Classification: Monoclonal Antibody
Cetuximab is a man-made version of a naturally occurring human/mouse antibody that inhibits the epidermal growth factor receptor (EGFR). The EGFR is a protein that is abnormally over-expressed in many cancers, and the inhibition of EGFR results in a decrease in tumor cell growth and decreased production of other factors responsible for metastasis (spreading of cancer).
How to Take Cetuximab
Cetuximab is given through intravenous (IV, into a vein) infusion. The first dose will be given over a period of about two hours. Subsequent doses will be given once a week, over about an hour. Medications are given prior to the administration of cetuximab to prevent a reaction to the infusion.
Possible Side Effects
There are a number of things you can do to manage the side effects of cetuximab. Talk to your doctor or nurse about these recommendations. They can help you decide what will work best for you. These are some of the most common side effects:
Some patients will develop a reaction to the medication. This most commonly occurs with the first dose. Reactions can cause chills, fever, shortness of breath, difficulty breathing, hoarseness, itching, or low blood pressure. Tell your nurse right away if you experience any of these. You will be given medication prior to the infusion to help prevent this reaction. You will be monitored for at least 1 hour after the completion of your infusion.
Nail and Skin Changes
Cetuximab has some unique nail and skin side effects that you may develop. Patients may develop a rash. While this rash may look like acne, it is not, and should not be treated with acne medications. The rash may appear red, swollen, crusty and dry and feel sore. You may also develop very dry skin, which may crack, be itchy or become flaky or scaly. The rash my be the worst during the first few weeks of treatment, but may continue until treatment is stopped. Tips for managing your skin include:
While receiving cetuximab, you may develop an inflammation of the skin around the nail bed/cuticle areas of toes or fingers, which is called paronychia. It can appear red, swollen or pus filled. Nails may develop "ridges" in them or fall off. You may also develop cuts or cracks that look like small paper cuts in the skin on your toes, fingers or knuckles. These side effects may appear several months after starting treatment, but can last for many months after treatment stops.
While receiving cetuximab, your eyelashes may grow very fast, become very long and bother your eyes. The hair on your head may become curly, fine or brittle. These changes tend to resolve once treatment is stopped.
Your oncology team can recommend medications to relieve diarrhea. Also, try eating low-fiber, bland foods, such as white rice and boiled or baked chicken. Avoid raw fruits, vegetables, whole grain breads, cereals and seeds. Soluble fiber is found in some foods and absorbs fluid, which can help relieve diarrhea. Foods high in soluble fiber include: applesauce, bananas (ripe), canned fruit, orange sections, boiled potatoes, white rice, products made with white flour, oatmeal, cream of rice, cream of wheat, and farina. Drink 8-10 glasses on non-alcoholic, un-caffeinated fluid a day to prevent dehydration.
Your doctor or nurse can recommend medication and other strategies to relive pain.
This medication can make your skin more sensitive to the sun, which can result in severe sunburn or rash. Sun sensitivity can last even after chemotherapy is completed. Limit sun exposure while receiving this medication, and for two months following the last dose. Avoid the sun between 10-2pm, when it is strongest. Wear sunscreen (at least SPF 15) everyday; wear sunglasses, a hat and long sleeves/pants to protect your skin and seek out shade whenever possible.
Fatigue is very common during cancer treatment and is an overwhelming feeling of exhaustion that is not usually relieved by rest. While on cancer treatment, and for a period after, you may need to adjust your schedule to manage fatigue. Plan times to rest during the day and conserve energy for more important activities. Exercise can help combat fatigue; a simple daily walk with a friend can help. Talk to your healthcare team for helpful tips on dealing with this side effect.
Cetuximab can cause interstitial lung disease (ILD), especially in those with pre-existing lung problems. You may have breathing tests (pulmonary function tests) performed periodically. Call your physician right away if you have shortness of breath, cough, wheezing or difficulty breathing.
Cetuximab can cause heart problems including cardiac arrest and heart attack. Patients with a prior history of coronary artery disease and/or receiving radiation therapy are at highest risk. Notify your healthcare team or go to the emergency room immediately if you experience chest pain, shortness of breath, or feel dizzy or faint.
This medication can impact the electrolyte levels in your blood; including magnesium, calcium and potassium. This can even occur after the completion of treatment. Your healthcare team will monitor your electrolyte levels during treatment, and for at least 8 weeks following the completion of treatment.
Exposure of an unborn child to this medication could cause birth defects, so you should not become pregnant or father a child while on this medication. Effective birth control is necessary during treatment and for 6 months after treatment has stopped. Even if your menstrual cycle stops or you believe you are not producing sperm, you could still be fertile and conceive. You should not breastfeed while receiving this medication, and for 2 months after your last treatment.
OncoLink is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through OncoLink should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem or have questions or concerns about the medication that you have been prescribed, you should consult your health care provider.
Information Provided By: www.oncolink.org | © 2016 Trustees of The University of Pennsylvania